These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32914327)

  • 21. Palliation of malignant bowel obstruction using a percutaneous cecostomy.
    Howie SB; Amigo PH; O'Kelly K; Fainsinger RL
    J Pain Symptom Manage; 2004 Mar; 27(3):282-5. PubMed ID: 15038342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous transgastric intestinal decompression: the management of malignant bowel obstruction without nasal intubation.
    Shinoda M; Kojima M; Fukase T; Ueno H; Ogihara T
    Surg Today; 1994; 24(10):937-9. PubMed ID: 7894197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous endoscopic gastrostomy for gastric decompression in metastatic gynecologic malignancies.
    Marks WH; Perkal MF; Schwartz PE
    Surg Gynecol Obstet; 1993 Dec; 177(6):573-6. PubMed ID: 8266267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide).
    Kapella M; Gana J; Decroisette E; Aubard Y
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):89-90. PubMed ID: 18684551
    [No Abstract]   [Full Text] [Related]  

  • 25. The safety of lanreotide for neuroendocrine tumor.
    Godara A; Siddiqui NS; Byrne MM; Saif MW
    Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous endoscopic gastrostomy/jejunostomy (PEG/PEJ) for decompression in the upper gastrointestinal tract. Initial experience with palliative treatment of gastrointestinal obstruction in terminally ill patients with advanced carcinomas.
    Scheidbach H; Horbach T; Groitl H; Hohenberger W
    Surg Endosc; 1999 Nov; 13(11):1103-5. PubMed ID: 10556447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer.
    Furnes B; Svensen R; Helland H; Ovrebo K
    Int J Surg; 2016 Mar; 27():158-164. PubMed ID: 26853847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palliative management of malignant bowel obstruction.
    Ripamonti C; Bruera E
    Int J Gynecol Cancer; 2002; 12(2):135-43. PubMed ID: 11975672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of palliative surgery in gynecologic cancer cases.
    Hope JM; Pothuri B
    Oncologist; 2013; 18(1):73-9. PubMed ID: 23299775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.
    Scherübl H; Wiedenmann B; Riecken EO; Thomas F; Böhme E; Räth U
    Eur J Cancer; 1994; 30A(10):1590-1. PubMed ID: 7833124
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of lanreotide in an elderly patient with Merkel cell carcinoma.
    Ghidini A; Petrelli F; Fazio I; Santangelo D
    Dermatol Ther; 2020 Jan; 33(1):e13206. PubMed ID: 31886588
    [No Abstract]   [Full Text] [Related]  

  • 32. [Percutaneous endoscopic gastrostomy (PEG) for palliative decompression drainage in inoperable ileus].
    Ritz MA; Arn M; Ballmer PE; Jost R
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1699-701. PubMed ID: 11103445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.
    Gayral F; Campion JP; Regimbeau JM; Blumberg J; Maisonobe P; Topart P; Wind P;
    Ann Surg; 2009 Dec; 250(6):872-7. PubMed ID: 19953707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement.
    Picus D; Marx MV; Weyman PJ
    AJR Am J Roentgenol; 1988 Feb; 150(2):295-7. PubMed ID: 2447767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of small-bowel obstruction after insertion of a percutaneous endoscopic gastrostomy tube due to mesenteric penetration.
    Roos J
    Ann R Coll Surg Engl; 2015 Jul; 97(5):e79-80. PubMed ID: 26264109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
    Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
    J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical management of bowel obstruction in gynaecological malignancies.
    Kolomainen DF; Barton DP
    Curr Opin Support Palliat Care; 2011 Mar; 5(1):55-9. PubMed ID: 21326004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
    Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
    Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal obstruction in patients with advanced gynecological cancer. A study of 62 cases.
    Emmert C; Schenker U; Köhler U
    Arch Gynecol Obstet; 1996; 258(4):213-8. PubMed ID: 8844139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.